SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indevus Pharmaceuticals (NasdaqNM:IDEV)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Arthur Radley1/30/2008 9:54:03 AM
   of 78
 
From AGN's Q report today.....appears they think it will be a good launch this year for Sanctura with revenue up to $100M

Outlook

For the full year of 2008, Allergan estimates:

Total product net sales between $4,395 million and $4,575 million.
-- Total specialty pharmaceuticals net sales between $3,525 million and $3,620 million.
-- Total core medical devices net sales between $870 million and $955 million.
-- ALPHAGAN® Franchise product net sales between $350 million and $380 million.

-- LUMIGAN® Franchise product net sales between $440 million and $460 million.

-- RESTASIS® product net sales between $375 million and $405 million.

-- SANCTURA® Franchise product net sales between $70 million and $100 million.

-- BOTOX® product net sales between $1,365 million and $1,415 million.

-- Breast aesthetics product net sales between $330 million and $350 million.
-- Obesity intervention product net sales between $315 million and $350 million.
-- Facial aesthetics product net sales between $225 million and $255 million.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News